study was subject to a number of major methodological flaws. Many of their claims pertain to the role of infant mortality …. I show that infant mortality was not an important determinant of the growth in U.S. life expectancy during the period … that I studied, and that my estimates are completely insensitive to the inclusion or exclusion of infant mortality …

mortality rates using longitudinal, annual, cancer-site-level data based on records of 2.1 million people diagnosed with cancer …

-adjusted cancer mortality rates of residents of France, using longitudinal, annual, cancer-site-level data during the period 2002 …I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-adjusted mortality rates of residents of Germany, using longitudinal, annual, state-level data during the period 2000-2007. The estimates …

-adjusted cancer mortality rates of residents of France, using longitudinal, annual, cancer-site-level data during the period 2002 …I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-adjusted mortality rates of residents of Germany, using longitudinal, annual, state-level data during the period 2000-2007. The estimates …

This paper investigates the impact of the introduction of new orphan drugs on premature mortality from rare diseases … two countries: the U.S. (during the period 1999-2006) and France (during the period 2000-2007). For both countries, we … estimate models using two alternative definitions of premature mortality, several alternative criteria for inclusion in the set …

pre‐dated factors that drove both innovation and mortality and that there would have been parallel trends in mortality in …I analyze the effects of four types of medical innovation and cancer incidence on US cancer mortality rates during the …-adjusted cancer mortality rate during 2000–2009. Drug innovation and imaging innovation are estimated to have reduced the cancer …